The promise of rituximab in connective tissue disease-associated interstitial lung disease
Main Article Content
Abstract
-
Downloads
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Seedat UF, Christian B, Boshoff PE, Gaylard P, Schleicher GK. Rituximab therapy in severe connective tissue disease-associated interstitial lung disease: A retrospective single-centre observational study. Afr J Thoracic Crit Care Med 2024;30(3):e1431. https://doi.org/10.7196/AJTCCM.2024.v30i3.1431
2. Bergantini L, d’Alessandro M, Cameli P, et al. Effects of rituximab therapy on B cell
differentiation and depletion. Clin Rheumatol 2020;39(5):1415-1421. https://doi.
org/10.1007/s10067-020-04996-7 org/10.7196/AJTCCM.2024.v30i3.XXXX
3. Liote H, Liote F, Seroussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease: A systematic literature review. Eur Respir J 2010;35(3):681-687. https://doi. org/10.1183/09031936.00080209
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-2833. https://doi.org/10.1200/JCO.1998.16.8.2825
5. Melet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab- induced T cell depletion in patients with rheumatoid arthritis: Association with clinical response. Arthritis Rheum 2013;65(11):2783-2790. https://doi.org/10.1002/art.38107
6. AliMF,EganAM,ShaughnessyGF,etal.AntifibroticsmodifyB-cell-inducedfibroblast migration and activation in patients with idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2021;64(6):722-733. https://doi.org/10.1165/rcmb.2020-0387OC
7. Thiam F, Phogat S, Abokor FA, Osei ET. In vitro co-culture studies and the crucial role of fibroblast-immune cell crosstalk in IPF pathogenesis. Respir Res 2023;24(1):298. https://doi.org/10.1186/s12931-023-02608-x
8. Wang Y, Li L. Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Int J Rheum Dis 2023;26(2):225-235. https://doi.org/10.1111/1756-185X.14495
9. Vacchi C, Manfredi A, Cassone G, Erre GL, Salvarani C, Sebastiani M. Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. Drugs Context 2021;10:2020-8-7. https://doi.org/10.7573/dic.2020-8-7
10. MaherTM,TudorVA,SaundersP,etal.Rituximabversusintravenouscyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): A double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 2023;11(1):45-54. https://doi.org/10.1016/S2213-2600(22)00359-9
11. Mankikian J, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): A double- blind, randomised, placebo-controlled trial. Eur Respir J 2023;61(6):2202071. https:// doi.org/10.1183/13993003.02071-2022
12. AdamsH,vandeGardeEMW,VugtsDJ,GruttersJC,OyenWJG,KeijsersRG.[89Zr]- immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: A phase 2 trial. Eur J Nucl Med Mol Imaging 2023;50(7):1929-1939. https://doi.org/10.1007/s00259-023-06143-1
13. Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. Lancet Rheumatol 2021;3(6):e419-e426. https://doi.org/10.1016/ S2665-9913(21)00059-X
14. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: Case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89(5):308- 318. https://doi.org/10.1097/MD.0b013e3181f2caef
15. Athni TS, Barmettler S. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Ann Allergy Asthma Immunol 2023;130(6):699-712. https://doi.org/10.1016/j.anai.2023.01.018
16. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;82(10):916-919. https://doi.org/10.1002/ajh.20910
17. Zayen A, Rais H, Rifi H, et al. Rituximab-induced interstitial lung disease: Case report and literature review. Pharmacology 2011;87(5-6):318-320. https://doi. org/10.1159/000327681
18. Subramanian M, Manjunath R, Kilara N, Mohan Rao KN. Rituximab-induced subacute interstitial pneumonitis: A case report and review of literature. J Cancer Res Ther 2010;6(3):344-346. https://doi.org/10.4103/0973-1482.73356
19. Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: Case report and review of the literature. Respiration 2008;76(4):449-453. https://doi.org/10.1159/000104866
20. Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJ. Non-infectious pulmonary toxicity of rituximab: A systematic review. Rheumatology (Oxford) 2012;51(4):653-662. https://doi.org/10.1093/rheumatology/ker290
21. Vulsteke C, Dierickx D, Verbeken E, Wolter P, Thomas J, Schoffski P. Rituximab- induced fatal interstitial pneumonitis: Case report. Leuk Lymphoma 2010;51(3):546- 548. https://doi.org/10.3109/10428190903518303
22. Andronache IT, Suta VC, Suta M, et al. Better safe than sorry: Rheumatoid arthritis, interstitial lung disease, and medication – a narrative review. Biomedicines 2023;11(6):1755. 23. Franzen D, Ciurea A, Bratton DJ, et al. Effect of rituximab on pulmonary function in patients with rheumatoid arthritis. Pulm Pharmacol Ther 2016;37:24-29. https://doi.
org/10.1016/j.pupt.2016.02.002
24. Division of Clinical Pharmacology, University of Cape Town, and South African Medical Association. South African Medicines Formulary. 15th ed. Last updated February 2024. https://samf-app.com (accessed 21 July 2024).
25. Hodkinson B, Blockman M. Strategies and ethics to ensure equitable access to biological medicines in the treatment of autoimmune inflammatory diseases. Curr Allergy Clin Immunol 2018;31(4):240-244.